Search
LZM012 in Phase III Clinical Trial for Psoriasis Treatment Meets Primary Endpoint
2025-07-21 /
Read about 0 minute
Author：小编
The Phase III clinical trial of LZM012, designed to treat moderate to severe plaque psoriasis, has successfully met its primary study endpoint. This multicenter, randomized, double-blind, and positive-control study represents a significant milestone. Consequently, the company has submitted an application for pre-marketing authorization to the Center for Drug Evaluation of the National Medical Products Administration.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
